Find in Library

Chronic myeloid leukaemia (CML) is a haematological neoplasm driven by the <i>BCR/ABL</i> fusion oncogene. The monogenic aspect of the disease and the feasibility of ex vivo therapies in haematological disorders make CML an excellent candidate for gene therapy strategies. The ability to abolish any coding sequence by CRISPR-Cas9 nucleases offers a powerful therapeutic opportunity to CML patients. However, a definitive cure can only be achieved when only CRISPR-edited cells are selected. A gene-trapping approach combined with CRISPR technology would be an ideal approach to ensure this. Here, we developed a CRISPR-Trap strategy that efficiently inserts a donor gene trap (SA-CMV-Venus) cassette into the <i>BCR/ABL</i>-specific fusion point in the CML K562 human cell line. The trapping cassette interrupts the oncogene coding sequence and expresses a reporter gene that enables the selection of edited cells. Quantitative mRNA expression analyses showed significantly higher level of expression of the <i>BCR/Venus</i> allele coupled with a drastically lower level of <i>BCR/ABL</i> expression in <i>Venus</i>+ cell fractions. Functional in vitro experiments showed cell proliferation arrest and apoptosis in selected <i>Venus</i>+ cells. Finally, xenograft experiments with the selected <i>Venus</i>+ cells showed a large reduction in tumour growth, thereby demonstrating a therapeutic benefit in vivo. This study represents proof of concept for the therapeutic potential of a CRISPR-Trap system as a novel strategy for gene elimination in haematological neoplasms.